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Abstract 
 
Aim of the present study was to formulate, evaluate and optimize the Pulsincap delivery system of deflazacort used 
in rheumatoid arthritis, based on the chronotherapeutic approach. The prepared pulsincap system consist of 
immediate release tablet sealed inside formaldehyde treated insoluble capsule body by hydrogel plug composed of 
polymer HPMC K15M and sodium alginate. Our target was to formulate a delivery system that could release the 
drug as per chronotherapeutic pattern of the disease (rheumatoid arthritis), so preliminary batches were prepared to 
study the effect of concentration of HPMC K15M and sodium alginate on the lag time of the drug release. 
Optimization of hydrogel plug was carried out by employing 32 full factorial design using Design expert 7 Software. 
The optimized batch of pulsincap sytem was found to release after a lag time of 366.66±2.887 minutes. 
 
Keywords: chronothepary, Deflazacort, Rheumatoid arthritis, Pulsincap, 32 Full factorial design. 
Introduction 
Convenience of administration and patient 
compliance are gaining significant importance in the 
design of dosage forms. The goal in drug delivery 
research is to develop formulations to meet 
therapeutic needs relating to particular 
pathological conditions. Research in 
the chronopharmacological field has demonstrated the 
importance of biological rhythms in drug therapy, and 
this has brought a new approach to the development of 
drug delivery systems1. Chronotherapeutic delivery 
system have drawn a increasing interest over a last few 
decades. This type of delivery system is able to release 
drug according to pulsatile pattern2. Recent studies 
have revealed that diseases have predictable cyclic 
rhythms and outcomes in selected chronic conditions 
can be improved by taking in account the timing of 
medication regimens3.  
Rheumatoid arthritis (RA) is a chronic systemic 
autoimmune inflammatory disease, associated with 
progressive disability, poor quality of life, and systemic 
complications.  
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It has been studies that RA follow circadian pattern. 
Reduced production of cortisol in the early 
morning and increased production of melatonin in the 
night influence the severity of early morning symptoms 
of RA4.  
In the present study, Deflazacort was selected as the 
model drug. Deflazacort is a glucocorticoid. 
Glucocorticoids have been used in RA therapy due to 
their anti-inflammatory activities against symptoms 
such as joint stiffness and joint pain. Cortisol is an 
endogenous glucocorticoid, which reaches the peak in 
the morning in humans. Steroids are generally 
administered in the morning in order to prevent 
disturbances in the circadian rhythms of endogenous 
glucocorticoids5,6. 
In order to obtain an appropriate formulation with 
minimum experiments, optimization method was 
adopted in the present study. A 32 full factorial design 
was chosen to optimize the variables. The search for 
the optimum was carried out using desirability function 
as this technique involves a way of overcoming 
difficulty of multiple, sometimes opposing responses. 
MATERIALS AND METHOD 
Materials 
Deflazacort, hydroxyl propyl methyl cellulose (HPMC 
K15M) and Avicel pH101 was obtained from Oscar 
Remedies Pvt. Ltd. Haryana, India, , sodium alginate, 
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sodium starch glycolate, talc and magnesium stearate 
was obtained from Nice Chemicals Pvt. Ltd. Kerala, 
India Ethylcellulose and ac-di-sol was obtained from 
Optica Pharmaceuticals, Haryana, India. Ethanol was 
obtained from modi mill, Yamuna nagar, Haryana. 
Drug-Excepient compatibility study by FTIR 
FTIR spectral analysis of physical mixture of drug and 
excipients was performed to assess drug excipients 
compatibility. Analysis was carried out by FTIR 
(Perkin Elmer 1600, USA) of Punjab University. 
Preparation of cross-linked gelatin capsule 
Hard gelatin capsules of size ‘1’ were taken and their 
bodies were separated from the caps and then bodies 
were placed on a wire mesh, kept inside a desiccator 
containing 25ml of 15%(v/v) formaldehyde and a pinch 
of potassium permanganate. The vapors of 
formaldehyde formed were exposed to body of the 
capsule. Reaction was carried out for 12h after 
which the bodies were removed and dried at 50°C for 
30 min to ensure completion of reaction between 
gelatin and formaldehyde vapors. Finally the bodies of 
the capsule were dried at room temperature to remove 
the excess of formaldehyde vapor7 , 8 
 
Test for formaldehyde treated empty capsule bodies 
Various physical tests, such as identification 
attributes, visual defects, changes in dimension  were 
carried out. 
Disintegration studies 
Study was carried out in USP-27/NF-22 disintegration 
test apparatus. A removable wire cloth was attached to 
the upper plate of basket after placing one capsule in 
each tube assembled in the disintegration apparatus. 
Time required for disintegration was noted for each 
capsule9.  
Qualitative chemical test for free formaldehyde 
 0.002w/v was used as the standard solution. 
Formaldehyde treated 25 body of the capsules were cut 
in to small pieces and taken into a beaker and dissolved 
with 40 ml of water. This was then stirred for 1 h with 
a magnetic stirrer, to solubilize the free formaldehyde. 
The solution was then filtered  into a 50 mL volumetric 
flask, washed with distilled water and volume was 
made up to 50 mL with the washings. From the 
prepared sample 1ml of sample was taken in a 10ml 
volumetric flask, 9ml of water was added to it; 1ml of 
the sample solution was taken into test tube and mixed 
with 4 ml of water and 5 ml of acetone. The test tube 
was kept in a water bath at 40 0C for 40 min. The same 
procedure was followed for 1 ml of standard 
formaldehyde solution. The color produced in the 
sample solution was compared with the color produced 
with the standard solution10. 
 
Preparation of immediate release tablets 
The composition of the immediate release tablets is 
given in table 1. The immediate release 
tablets containing drug deflazacort, sodium strarch 
glycolate and ac di sol were prepared by weighing the 
drug, sodium strarch glycolate, ac di sol and mixing 
with Avicel pH 101. Magnesium stearate (1%) and talc 
(2%) were added to each blend and further mixed. The 
resultant blends were tableted to 30 mg using 3 mm 
round flat-faced punches using a single punch tablet 
press (single station tablet compression machine, Rolex 
scientific Eng. Haryana, India) 
Evalution of immediate release tablets 
The thickness and diameter of the tablets (n=10) were 
determined using micrometer11. The hardness of the 
tablets (n=10) was determined by using the pfizer 
hardness tester12 Electrolab, Mumbai, India. The 
friability (%) of the tablets was determined by taking 
Sample of whole tablets corresponding to about 6.5gm  
placed in the friabilator and were subjected to 100 
revolutions13. The tablets were taken out, de dusted and 
reweighed to determine the friability of all the batches. 
Weight variation test of the tablets (n=20) was carried 
out as per the official method14. The disintegration time 
of core tablets was determined by the Disintegration 
tester USP15 (ED-2AL, Electrolab, Mumbai, India). 
For determining the drug content immediate release 
tablet was crushed in a glass mortar and transferred 
quantitatively with methanol in a stoppered conical 
flask. The flask was placed in a sonicator for 30 min. 
The mixture was filtered and an aliquot, following 
suitable dilution, was analyzed at 242 nm using a UV 
spectrophotometer. The drug content was determined 
using a calibration curve constructed in methanol. The 
drug content of each of the ten immediate release 
tablets was compared with the average drug content of 
the tablets16 
 Preparation of hydrogel plug 
Hydrogel plugs (preliminary batches) were prepared by 
direct compression according to the formula mentioned 
in table 2. The average weight of hydrogel plug was 
found to be 100mg. HPMC/ sodium alginate polymers 
were properly blended with Avicel pH101 using a 
mortar and pestle. The resultant blend was lubricated 
with the addition of lubricant magnesium stearate and 
finally compressed into plug (100 mg) using 5 mm 
round flat punches. 
Evaluation of hydrogel plug 
Hydrogel plug containing HPMC and sodium alginate 
were evaluated for weight variation, thickness and 
hardness. 
Development of pulsincap system 
Prepared immediate release tablet was placed in the 
capsule size 1 and the prepared hydrogel plug was 
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introduced into the open end of the capsule body. 
Finally the soluble capsule cap was placed over the 
capsule body. The joint of formaldehyde treated 
capsule body and soluble cap was further sealed with 
5% Ethylcellulose ethanolic solution. 
In vitro dissolution study of the capsule 
The dissolution studies of prepared pulseincap 
formulations were carried out using USP type II 
dissolution test apparatus. The capsules were tied to 
paddle with a cotton thread so that the capsules get 
completely immersed  in dissolution vessel containing 
containing 700ml of 0.1N HCl (pH 1.2 i.e gastric pH) 
and the study was carried out for 2h, taking 6ml sample 
at an interval of 30min. Then 200 ml of 0.2 (M) 
trisodium orthophosphate dodecahydrate solution was 
added quickly and pH was adjusted using a pH meter 
to pH 7.4( i.e small intestine pH). Samples (6 ml) were 
collected periodically at different time intervals. 
Experimental design 
A two factor, three level (32) FFD was used in the 
optimization of Hydrogel plug. The study design 
involved the investigation of the effect of independent 
variables viz concentration of HPMC (X1) and 
concentration of sodium alginate (X2) on the dependent 
variable lag time. The combination of these trials is 
presented in Table 3 
The levels of the factors studied were chosen on the 
basis of results of preliminary studies, so that their 
relative difference was adequate to have a measurable 
effect on the response, along with the information that 
the selected levels are within practical use. After 
developing the experimental design nine batches of 
hydrogel plug were formulated. Nine formulations 
(Table 4) were prepared according to the experimental 
design. 
The factorial design is a simplified representation in 
analytical form of a given reality. In this mathematical 
approach, each experimental response Y can be 
represented by a quadratic equation of the response 
surface: Y = β0 + β1 X1 + β2 X2+ β3 X1 X2 + β4 X12 + β5 
X22, in which Y is the measured response associated 
with each factor-level combination; X1 and X2 are the 
factors studied; B0 is an intercept; B1– B5 are the 
regression coefficients. The equation enabled the 
study of the effects of each factor and their interaction 
over the considered responses. 
Optimization of hydrogel plug 
The optimization process was used to obtain a model 
equation that provides a means of evaluating changes 
in response due to changes in the independent variable 
levels. After application of full factorial design and 
with help of polynomial terms the optimized pulsincap 
system (H1) was produced. Pulsincap formulation was 
prepared as per the composition given in table 5. This 
batch targeted to lag time 360 min. the observed 
response for lag time was 366.66±2.887.  
Stability studies 
In order to assess stability, the optimum pulsincap of 
deflazacort were packed in an amber colored air tight 
vial and stored at (40 ± 2 °C and 75 ± 5% RH) for a 
period of 6 months. The formulations were withdrawn 
after a particular period of time, analyzed for physical 
appearance, weight, drug content, and lag time. At 
this point, the data was statistically analyzed using 
ANOVA to test the significance of difference at the 
level of significance 0.05. 
RESULTS AND DISCUSSION 
Preformulation studies 
Drug and excipient studies were performed and FTIR 
studies revealed that there is no 
incompatibility between drug and excipients used in 
the study. FTIR spectra of DZ and physical mixture of 
(DZ:HPMC), and (DZ:SA) are shown in Fig. 1. Among 
the various bands obtained in the spectra of DZ, only 
important ones were identified. An IR band was 
obtained at 3455.8 which can be assigned to OH stretch 
vibration, 1746.4, 1730.1 and 1654 were assigned to 
22-C=O the 20-C=O and the cyclic α–β unsaturated 3-
ketone (3- C=O)  respectively. All these functional 
groups indicate purity of the drug. In physical mixture 
of DZ and HPMC, the characteristic absorption peaks 
of DZ appeared at 3455.8 cm-1 indicating OH stretch 
vibration, 1746.6, 1730 and  1654.8cm-1 22-C=O the 
20-C=O and the cyclic α–β unsaturated 3-ketone (3- 
C=O) respectively. 
In DZ:SA physical mixture, all the above mentioned IR 
bands were identified and no significant shift in peak 
was observed with respect to drug and polymer, which 
signifies very less to no chemical interaction between 
drug and the polymers. 
Physical test 
It was found that after formaldehyde treatment the 
length and dimension of capsule bodies were decreased 
Disintegration test of capsules 
It was found that the untreated capsules and the caps of 
treated capsules were disintegrated within 20 min. 
whereas the treated capsules remained intact for 24 
hours 
Formaldehyde treatment of empty gelatin capsule 
Formalin treatment has been employed to modify the 
solubility of the gelatin capsules. Exposure to 
formalin vapours results in an unpredictable decrease 
in solubility of gelatin owing to the cross-linkage of the 
amino groups in the gelatin molecular chain with 
aldehyde groups of formaldehyde by Schiff’s base 
condensation. The solubility tests were carried out for 
untreated capsules and formaldehydetreated capsules 
for 24 h. It was observed that in all untreated capsules, 
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both cap and body dissolved within 30 min, whereas in 
formaldehyde-treated capsules, only the cap dissolved 
within 30 min, while the capsule body remained intact 
for about 24 h and hence indicates the suitability for 
colon targeting. The formaldehyde capsules were tested 
for the presence of free formaldehyde. The sample 
solution was not more intensely coloured than the 
standard solution, inferring that less than 0.8 mg of free 
formaldehyde per capsule was present as 
residual amount. 
Evaluation of prepared powder blend  
Prepared powder blend of immediate release core tablet 
and hydogel plug was subjected to evaluate various 
micromeritic properties. It was found that the powder 
exhibit good flow property as evident from the table 6 
and 7 
Evaluation of prepared immediate release tablet 
Prepared immediate release tablets were subjected to 
check various physico-chemical properties and the 
values were found within the limits. Results are 
depicted in table 8 
Evaluation of compressed hydrogel plug and 
pulsincap system 
After formulating preliminary batches of hydrogel 
plugs, the evaluation study of hydrogel plugs were 
carried out, and the results obtained are represented in 
Table 9. It was found that all the formulations 
exhibited uniform weight with low standard deviation 
values, indicating the uniformity of the weight in 
hydrogel plugs prepared by direct compression method. 
The weight of the hydrogel plug varied between 102.72 
mg and 98.48 mg. Range of  hydogel plug thickness 
was found to be between 5.92mm – 6.28mm.  
Hardness of hydrogel plug was determined by Pfizer 
hardness tester taking average of ten hydrogel plugs. It 
was found that with the increase in concentration of 
polymer there was an increase in the hardness value of 
plug. Range of hardness for hydrogel plug was in 
between 2.68 kg/cm2 – 3.93 kg/cm2 with minimum 
standard deviation. 
In vitro dissolution studies 
In vitro drug release from pulsincap delivery sytem 
containing hydrogelplug with varying polymer 
concentration is depicted fig 2. each formulation 
released the drug after a certain lag time and the lag 
time attained was dependant on type and concentration 
of polymer. It was found that maximium lag time (430 
min) was shown by the formulation HG3 containing 
60% of HPMC and minimum lag time (180 min) was 
shown by formulation HG4 containing 20% of sodium 
alginate. Lag time found in the formulation HG7 – 
HG9 containing HPMC and sodium alginate in 
combination was 330 min – 400 min. 
On the basis of preliminary studies it was found that 
with increase in the concentration of the polymer the 
lag time of drug release was also increased. On the 
basis of values of hardness obtained it was observed 
that with decreasing the concentration of polymer value 
of hardness also decreased. In case of formulation 
HG7-HG9 improved hardness values were obtained. 
Based on these findings combination of polymer was 
selected for further studies. 
Statistical and response surface analysis of models 
for lag time  
Statistical analysis 
It was investigated, lag time showed a wide variation 
with change in concentration of two factors. Table 10 
describes effect of HPMC and sodium alginate. It was 
found that with increase in concentration of HPMC and 
sodium alginate lag time for drug release also 
increased. According to dissolution profile it was found 
that lag time OHG1-OHG9 (fig. 3) varied between 
300-440 min. Formulation OHG2 released drug after a 
lag time of 370 min. and the percentage of drug 
released from the formulation was found to be  
95.85%. 
Optimization  
Optimization was done employing a 32 FFD. The 
dependent and independent variables were related 
using quadratic equations obtained with the Design 
Expert software (Design Expert 7) For each dependent 
variable, a summarizing equation was generated as 
shown in Table 11. ANOVA was performed to identify 
insignificant factors. Model selection was based on 
lower p values than assigned significance level, high F 
value i.e. 26.961, absence of lack of fit, highest level 
of adjusted R2 and predicted R2, low standard deviation 
and lower PRESS value. All values are represented in 
Table 12. All values implies the model is significant. 
High value of R2 for dependent variable was obtained, 
which indicate a good fit. Value of p less than 0.05 
indicated that model terms are significant. 
Response surface analysis 
Response surface plot was generated for response to 
study the behavior of the system. Response surface 
plot for hardness in fig. 4 shows that with the increase 
in the concentration of HPMC lag time of drug 
increases in linear manner and with increase in 
concentration in SA the lag time value of the hydrogel 
plug also increases in a curvilinear manner. 
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Table 1: Composition of immediate release tablet 
 
Batch 
Ingredients (mg) 
Deflazacort 
Sodium starch 
glycolate 
Ac-Di-Sol Talc 
Magnesium 
stearate 
Avicel pH101 
Immediate 
release 
tablet 
6 1.8 1.974 0.6 0.3 19.36 
 
Table 2: Trial batches of hydrogel plug 
 
 
            Batch 
Hydrogel plug material (mg) 
HPMC Sodium alginate Avicel pH101 Magnesium stearate 
HG1 20 - 79 1 
HG2 40 - 59 1 
HG3 60 - 39 1 
HG4 - 20 79 1 
HG5 - 40 59 1 
HG6 - 60 39 1 
HG7 20 60 19 1 
HG8 40 40 19 1 
HG9 60 20 19 1 
 
Table 3 Experimental plan of 32 full factorial design 
 
Formulation 
Code 
HPMC 
(X1) 
Sodium alginate 
(X2) 
OHG1 -1 -1 
OHG2 0 -1 
OHG3 +1 -1 
OHG4 -1 0 
OHG5 0 0 
OHG6 +1 0 
OHG7 -1 +1 
OHG8 0 +1 
OHG9 +1 +1 
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Table 4 Formulation of experimental batches of pulsincap formulation 
Formulation code Immediate release 
tablet (mg) 
Hydrogel composition (mg) 
HPMC 
 
Sodium 
alginate 
Avicel 
pH101 
Magnesium 
stearate 
OHG1 30 50 45 4 1 
OHG2 30 40 45 14 1 
OHG3 30 30 45 24 1 
OHG4 30 50 40 9 1 
OHG5 30 40 40 19 1 
OHG6 30 30 40 29 1 
OHG7 30 50 35 14 1 
OHG8 30 40 35 24 1 
OHG9 30 30 35 34 1 
  
Table 5 Composition of optimum batch (mg) of pulsincap formulation 
Batch 
Immediate 
release tablet 
(mg) 
HPMC Sodium alginate 
Magnesium 
stearate 
Avicel pH101 
H1 30 40 37.65 1 21.35 
 
Table 6: Characterization of powder blends of immediate release tablet 
 
F.Code 
Bulk 
Density* 
(g/cc) 
Tapped Density* 
(g/cc) 
Hausner’s   
Ratio** 
Compressibility 
Index (%)** 
Angle of Repose* 
(o) 
F1 0.492±.003 0.558±.011 1.134 11.827 15.844±0.805 
F2 0.498±.008 0.581±.008 1.166 14.285 14.248±0.602 
F3 0.559±.009 0.652±.011 1.166 14.263 15.093±0.92 
F4 0.556±.010 0.662±.010 1.191 16.012 14.676±0.606 
F5 0.551±.011 0.682±.011 1.238 19.208 10.506±0.833 
F6 0.559±.012 0.612±.007 1.023 8.660 13.929±1.113 
F7 0.549±.013 0.622±.013 1.133 11.736 14.844±0.702 
F8 0.561±.012 0.619±.008 1.103 9.369 10.248±0.501 
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F9 0.553±.006 0.633±.013 1.145 12.638 11.093±0.620 
F10 0.545±.007 0.617±.004 1.132 11.669 14.676±0.416 
F11 0.564±.009 0.629±.013 1.115 10.333 12.506±0.723 
F12 0.541±.014 0.614±.010 1.135 11.889 13.929±1.113 
* n=3; ** Calculated from average values of tapped density and bulk density. 
Table 7: Characterization of powder blends of hydrogel plug 
F.Code  Bulk Density* (g/cc)  Tapped Density* (g/cc)  
Hausner’s   
Ratio**  
Compressibility 
Index (%)**  
Angle of 
Repose* (o)  
HG1  0.416±0.006 0.488±0.01 1.17 14.73 15.47±0.815 
HG2  0.481±0.014 0.526±0.011 1.094 8.63 15.62 ±0.91 
HG3  0.460±0.013 0.515±0.01 1.12 10.714 14.956±0.701 
HG4  0.510±0.013 0.564±0.009 1.104 9.498 16.57 ±0.52 
HG5  0.526±0.014 0.570±0.009 1.083 7.691 16.82 ±0.82 
HG6  0.561±0.011 0.669±0.013 1.192 16.107 16.64 ±0.53 
HG7  0.575±0.018 0.619±0.011 1.078 7.243 16.494± 0.71 
HG8  0.575±0.017 0.635±0.012 1.104 9.448 15.83±0.63 
HG9  0.487±0.014 0.556±0.006 1.141 12.41 15.364±0.612 
* n=3; ** Calculated from average values of tapped density and bulk density 
Table 8: Characterization of immediate release tablets 
Batch 
Average 
Weight (gm) * 
Thickness 
(mm)*** 
Hardness 
(Kg/cm2)*** 
Disintegration 
Time (s)***** 
Friability 
(%)**** 
Drug 
content 
(%)** 
Immediate 
release 
tablets 
30.86±2.634 3.26±0.071 3.0±0.15 64.167±3.502 0.598 99.36 
*Each value is average of twenty independent determinations; **Each value is average of five tablets; ***Each 
value is average of ten independent determinations; ;**** Each value is average of two hundred sixteen tablets. 
***** Each value is average of six independent determinations 
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Table 9: Characterization of Hydrogel plugs 
 
Formulation 
Code 
Weight variation (mg) 
(Mean±SD)*** 
Thickness 
(mm)                                                                                                  
(Mean±SD)*** 
Hardness**** 
(Kg/cm2)
 
HG1 100.25±4.989 6.044±0.089 3.57±0.199 
HG2 99.6±3.072 6.1576±0.086 3.65±0.133 
HG3 100.15±3.531 6.0953±0.112 3.93±0.134 
HG4 101.4±3.627 6.006±0.128 2.68±0.175 
HG5 102.74±4.701 6.1608±0.074 2.72±0.171 
HG6 98.48±2.988 6.0313±0.097 2.78±0.177 
HG7 102.36±3.423 6.28±0.103 2.91±0.231 
HG8 100.15±2.901 5.920±.154 3.31±0.148 
HG9 102.72±3.86 6.21±.099 3.62±0.206 
*** Each value is average of twenty independent determinations; **** Each value is average of ten independent 
determinations. 
Table 10: Effect of polymer concentration on the characteristics of the prepared pulsincap formulations 
F. 
Code 
Conc. of HPMC  (%) 
Conc. of sodium alginate 
(%) 
Lag Time* (min) 
OHG1 50 45      440±3.65 
OHG2 40 45 370±4.37 
OHG3 30 45 330±5.31 
OHG4 50 40 410±6.188 
OHG5 40 40 380±4.51 
OHG6 30 40 330±5.58 
OHG7 50 35 390±2.70 
OHG8 40 35 340±4.67 
OHG9 30 35 300±2.54 
* n=3 
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Table 11: The quadratic equations relating lag time with independent variables in pulsincap formulation 
Response 
Experiment Parameters 
β0 β1 β2 β3 β4 β5 
Lag Time 
371.1111 
 
46.66667 
 
18.33333 
 
5 
 
3.333333 
 
-11.6667 
 
  
Table 12: ANOVA results model in pulsincap formulation 
Measured 
Response 
SS DF MS F-Value Prob > F SD R2 
Lag Time 15477.78 5 3095.556 26.961 0.0107 10.715 0.978 
SS- sum of squares, DF- degree of freedom, MS- Mean square, SD- Standard deviation 
 
 
 
 
Figure 1 Scanned FTIR spectra of (a) Deflazacort (b) Physical mixture of Deflazacort and HPMC K15M (C) 
Physical mixture of deflazacort and sodium alginate 
 
 
Asian Pac. J. Health Sci., 2018; 5(4):210-220                                           e-ISSN: 2349-0659, p-ISSN: 2350-0964 
____________________________________________________________________________________________________________________________________________  
 ____________________________________________________________________________________________________________________________________________ 
Raina et al                  ASIAN PACIFIC JOURNAL OF HEALTH SCIENCES, 2018;5(4):210-220                                  219 
www.apjhs.com       
 
 
 
Figure 2: Percent released of Deflazacort from pulsincap system (preliminary batch) 
 
 
 
Figure 3 Percent released of Deflazacort from pulsincap system (Experimental batch) 
 
 
 
 
Figure 4: Response surface graph showing the influence of X1 and X2 on the Lag time of pulsincap system of 
deflazacort 
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Accelerated stability studies 
Accelerated stability studies on the optimized 
promising formulation  of pulsincap (H1) was carried 
out by storing the formulations (in amber colored 
rubber stoppered vials) at 40±20C and 75±5% RH for 6 
months. At regular intervals the formulation was 
characterized for different parameters. It is shown that 
there was no change in physical appearance, weight, 
hardness, drug content during the study period and at 
the end of the six months. Also no significant change 
was shown in the percent drug release, before and after 
storage. Thus, results imply good stability of the 
formulation on six month storage.  Since the 
accelerated data showed little or no change over time 
and little variability, a statistical analysis was 
considered unnecessary. 
 
Conclusion 
It was concluded that, implementation of a suitable 
experimental design results in achievement of an 
appropriate formulation, in the shortest time with 
minimum efforts. Pulsincap formulation of deflazacort 
prepared by using polymer HPMC and sodium alginate 
was found to be better alternative for the patients 
having rheumatoid arthritis that follows the circadian 
pattern because the prepared formulation released the 
drug according to the need of disease. Lag time for the 
release of drug from the optimized formulation was 
found to be 366.66±2.887 which was in close 
proximity to the desired value. Thus it can be said that 
our prepared formulation might be beneficial in a 
diseased state to provide relief at its worst condition. 
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